Quanttus raises $19M in Series A round from Khosla Ventures and Matrix Partners
Khosla Ventures and Matrix Partners invested $19 million in the Series A round of Quanttus, a statement about the funding said.
The latest financing comes after the seed round of $3 million led by Vinod Khosla of Khosla Ventures. Proceeds from the round will be used to improve "clinical-grade vital signs monitoring and advances in contextual analysis" so that the company can develop wearable devices that actually enable individuals to get to know and understand their bodies better and enhance their health, the statement said.
Experts from such illustrious organizations as The Massachusetts Institute of Technology, Nike, Apple, IDEO and Massachusetts General Hospital developed the Quanttus platform that is made up of two components. First, the company's wearable technologies are capable of capturing and evaluating over half a million vital sign data points on a daily basis. The second component is that applications are able to decode these data points into real-time insights that allow people to choose practices that can enhance their wellbeing, the statement said.
Quanttus Co-Founder and Chief Executive Officer Shahid Azim said in the statement, "From busy professionals to those focused on living a healthy lifestyle, athletes to people living with chronic health conditions, we want to help the world get better and be better with wearable devices and digital experiences that blend with life instead of interrupting it. The investment and expertise of Khosla Ventures and Matrix Partners will help us further validate our vision for continuous health monitoring and bring Quanttus to market."
In the statement, Quanttus said our bodies give millions of signals regarding our state of health every day but these are barely recognized until we actually get sick. The company said this should not be the case.
Vinod Khosla of Khosla Venturs said in the statement, "Quanttus is pushing monitoring into many high value use cases from cardiac disease and hypertension monitoring to stress. The team's approach to using real-time physiological data will create powerful new tools for consumers and healthcare providers that will change how we understand our health."